Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Tularik describes agents for lipoprotein disorders acting via a novel mechanism

Aug. 19, 1999

Parathyroid hormone prolongs the survival of osteoblasts

Aug. 19, 1999

Kissei prepares beta3-adrenoceptor stimulants as novel antiobesity agents

Aug. 18, 1999

FDA accepts PMA for OP-1 Implant

Aug. 18, 1999

Merck's newest alphavbeta3 ligands prevent osteoclast-mediated bone resorption

Aug. 16, 1999

Triazepinone compounds from Merck KGaA act as AGE formation inhibitors

Aug. 16, 1999

Pfizer redirects zopolrestat development program

Aug. 13, 1999

Buccal insulin effective in controlling postprandial hyperglycemia

Aug. 13, 1999

Glaxo Wellcome invention describes hypolipidemic activity of novel benzothiazepines

Aug. 13, 1999

Metabolex and Iconix to collaborate on diabetes drug discovery

Aug. 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...